Table 2.
Univariable Cox models showing the association between study variables at baseline and achievement of steroid-free clinical and biochemical remission.
| Variable | HR | 95% CI | P value |
|---|---|---|---|
| Age at diagnosis (OR per year) | 1.01 | 0.99-1.03 | .24 |
| Age at ustekinumab initiation (OR per year) | 1.01 | 0.99-1.03 | .15 |
| Disease duration (OR per year) | 1 | 0.97-1.04 | .85 |
| Sex | |||
| Female (ref) | — | — | — |
| Male | 0.73 | 0.43-1.25 | .26 |
| Race | |||
| Not NHW (ref) | — | — | — |
| NHW | 0.43 | 0.22-0.83 | .01a |
| Smoking status | |||
| Never (ref) | — | — | — |
| Current | 1.42 | 0.17-12.07 | .73 |
| Past | 0.79 | 0.42-1.47 | .46 |
| Previous hospitalizations | |||
| No (ref) | — | — | — |
| Yes | 0.56 | 0.32-0.98 | .04a |
| Body mass index (OR per unit) | |||
| Partial Mayo score at baseline (OR per unit) | 0.99 | 0.97-1.03 | .97 |
| History of extraintestinal manifestations | 0.75 | 0.63-0.89 | .001a |
| No (ref) | — | — | — |
| Yes | 1.03 | 0.58-1.81 | .92 |
| Previous us of aminosalicylates | |||
| No (ref) | - | - | - |
| Yes | 0.49 | 0.18-1.30 | .15 |
| Previous use of methotrexate | |||
| No (ref) | — | — | — |
| Yes | 1.1 | 0.56-2.11 | .79 |
| Previous use of thiopurine | |||
| No (ref) | — | — | — |
| Yes | 0.9 | 0.53-1.53 | .7 |
| Disease extent | |||
| E1 (ref) | — | — | — |
| E2 | 3.19 | 0.61-24.16 | .19 |
| E3 | 1.37 | 0.29-9.79 | .71 |
| Concomitant use of corticosteroids | |||
| No (ref) | — | — | — |
| Yes | 0.46 | 0.27-0.79 | .005a |
| Concomitant use of immunomodulators | |||
| No (ref) | — | — | — |
| Yes | 0.69 | 0.25-1.71 | .44 |
| Concomitant use of aminosalicylates | |||
| No (ref) | — | — | — |
| Yes | 1.76 | 0.82-3.81 | .14 |
| Exposure to anti-TNF only | |||
| No (ref) | — | — | — |
| Yes | 1.28 | 0.68-2.39 | .43 |
| Exposure to anti-TNF and vedolizumab only | |||
| No (ref) | — | — | — |
| Yes | 0.53 | 0.29-0.95 | .04a |
| Exposure to vedolizumab only | |||
| No (ref) | — | — | — |
| Yes | 1.09 | 0.48-2.39 | .83 |
| Exposure to anti-TNF, vedolizumab, and tofacitinib | |||
| No (ref) | — | — | — |
| Yes | 0.81 | 0.40-1.58 | .54 |
| Baseline C-reactive protein (OR per mg/dL) | 0.98 | 0.95-1.01 | .26 |
| Baseline albumin (OR per g/dL) | 2.15 | 1.07-4.65 | .04a |
Steroid-free clinical and biochemical remission was denied as partial Mayo score <2 while off steroids with a normal C-reactive protein and/or fecal calprotectin.
Abbreviations: CI, confidence interval; HR, hazard ratio; NHW, non-Hispanic White; OR, odds ratio; TNF, tumor necrosis factor.
aStatistically significant.